Education
About Us
Working with TipRanks
Follow Us
Sernova Corp (DE:PSH0)
XETRA:PSH0
PSH0 Stock Chart & Stats
€0.11
--
Market closed
€0.11
--
Day’s Range― - ―
52-Week Range€0.06 - €0.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)4.46K
Market Cap
€35.20M
Enterprise Value€72.57M
Total Cash (Recent Filing)€265.00K
Total Debt (Recent Filing)€17.28M
Price to Earnings (P/E)―
Beta-0.17
Next Earnings
Mar 19, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding336,698,550
10 Day Avg. Volume5,531
30 Day Avg. Volume4,462
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-1.96
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform Technology — Cell Pouch SystemSernova’s Cell Pouch is a platform implantable-device approach that can host multiple therapeutic cell types. Platform-led technologies provide durable optionality across indications, enable repeated product iterations, and can support multiple downstream partnerships or licensing routes if clinical proof-of-concept is achieved.
Improving Cash Burn TrajectorySteady reduction in operating cash burn and net loss over multi-year periods demonstrates management focus on spending discipline and program prioritization. A sustained decline in burn improves runway dynamics and reduces frequency and magnitude of future financings, supporting longer-term program continuity.
Balance-sheet Relief From Corporate ActionsDebt-to-equity conversion and financings materially alter capital structure by lowering immediate cash interest burdens and converting obligations to equity. This structural change improves near-term liquidity and aligns creditors as equity holders, lowering short-term default risk and supporting ongoing clinical programs.
Bears Say
Negative Equity And Rising LeverageThe move to materially negative equity combined with a sharp increase in debt reflects heightened solvency risk and weaker creditor protection. Over the medium term this increases refinancing and dilution risk, constrains strategic options, and can hamper ability to attract non-dilutive partners or favorable financing terms.
Pre-revenue, Development-stage ProfileAbsent commercial revenues, Sernova’s value and cash runway depend entirely on clinical outcomes, milestones, and external funding. This creates binary program risk and long lead times to sustainable margins; failure or delays in trials would materially impair long-term viability and partnership prospects.
Negative Free Cash Flow; Ongoing Funding NeedPersistently negative free cash flow means the company remains dependent on external capital for operational continuity. Recurrent financing needs increase dilution risk, may force prioritization or cuts to R&D, and reduce negotiating leverage with potential partners or acquirers over the medium term.
Sernova News
PSH0 FAQ
What was Sernova Corp’s price range in the past 12 months?
Sernova Corp lowest stock price was €0.06 and its highest was €0.20 in the past 12 months.
What is Sernova Corp’s market cap?
Sernova Corp’s market cap is €35.20M.
When is Sernova Corp’s upcoming earnings report date?
Sernova Corp’s upcoming earnings report date is Mar 19, 2026 which is in 8 days.
How were Sernova Corp’s earnings last quarter?
Sernova Corp released its earnings results on Dec 19, 2025. The company reported -€0.003 earnings per share for the quarter, beating the consensus estimate of -€0.006 by €0.003.
Is Sernova Corp overvalued?
According to Wall Street analysts Sernova Corp’s price is currently Overvalued.
Does Sernova Corp pay dividends?
Sernova Corp does not currently pay dividends.
What is Sernova Corp’s EPS estimate?
Sernova Corp’s EPS estimate is >-0.01.
How many shares outstanding does Sernova Corp have?
Sernova Corp has 336,698,550 shares outstanding.
What happened to Sernova Corp’s price movement after its last earnings report?
Sernova Corp reported an EPS of -€0.003 in its last earnings report, beating expectations of -€0.006. Following the earnings report the stock price went up 24.39%.
Which hedge fund is a major shareholder of Sernova Corp?
Currently, no hedge funds are holding shares in DE:PSH0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sernova Corp
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.
Technical Analysis
Covalon Technologies
―
Microbix Biosystms
―
Medmira
―
NurExone Biologic
―
Defence Therapeutics
―